Full Text
Abstract
Introduction. The number of patients with diabetes mellitus (DM) type 2 undergoing coronary bypass surgery (CBS) increas- es from year to year. Effectiveness of antiaggregant therapy in postoperative period is extremely important for such patients because of high risk of shunts thrombosis.
Aim of study: assessment of effectiveness of acetylsalicylic acid (ASA) usage in patients with DM and coronary heart disease and the effect of ASA-resistance on the development of shunts occlusions in the long-term period after CBS.
Materials and methods. The study included 40 men with DM type 2 diabetes after CBS; the comparison group included 47 patients without DM. In all patients we examined platelet aggregation on 14 day after surgery. Within the next 2 years after surgery 23 patients with DM come through coronary shuntography for assessment of bypass patency.
Results. Among 40 examined patients 15 had laboratory signs of ASA-resistance. There was no correlation between age, obesity, blood pressure, degree of control over diabetes and development of ASA-resistance. In patients with diabetes we found inverse negative relationship between the level of platelet aggregation and fibrinogen concentration, content of solu- ble fibrin-monomer complexes, and von Willebrand factor. The existence of ASA-resistance did not lead to high frequency of shunts occlusion in comparison with ASA-sensitive patients.
Conclusion. The proportion of ASA-resistance patients was 37.5%. ASA-resistance was not a predictor of shunts occlusion in patients with DM after CBS.
REFERENCES
1. Shal’nova S. A., Oganov R. G., Deev A. D., Imaeva A. E. Comor- bidities of ischemic heart disease with other non-communica- ble diseases in adult population: age and risk factors association. [Sochetaniya ishemicheskoy bolezni serdtsa s drugimi neinfektsi- onnymi zabolevaniyami v populyatsii vzroslogo naseleniya: assot- siatsiya s vozrastom i faktorami riska]. Kardiovaskulyarnaya tera- piya i profilaktika. 2015; 14 (4): 44–51 (in Russ.).
2. Kim J. H., Kim D. J., Jang H. C. et al. Epidemiology of micro- and macrovascular complications of type 2 diabetes in Korea. Diabe- tes Metab J. 2011; 35 (6): 571–7. DOI: 10.4093/dmj.2011.35.6.571. PMID: 22247898.
3. Tanashyan M. M., Domashenko M. A., Raskurazhev A. A. Aspirin resisttance: clinical and molecular genetic evalution techniques. [Aspirinorezistentnost’: klinicheskiye i molekulyarnyye metodi- ki otsenki]. Annaly klinicheskoy i eksperimental’noy nevrologii. 2016; 10 (1): 41–4 (in Russ.).
4. Sidorenko I. V. Resistance to acetylsacyclic acid: the current state of the problem. [Rezistentnost’ k acetilsalicilovoj kislote: sovre- mennoye sostoyaniye problemy]. Meditsinskiye novosti. 2013; 9: 12–3 (in Russ.).
5. Jastrzębska M., Chełstowski K., Wódecka A. et al. Factors influ- encing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study. Blood Coagul Fibrinolysis. 2013; 24 (8): 830–8. DOI: 10.1097/MBC. 0b013e3283655640. PMID: 24071649.
6. Grimaldi R., Bisi M., Lonni E. et al. Laboratory aspirin resistance reversibility in diabetic patients: a pilot study using different phar- maceutical formulations. Cardiovasc Drugs Ther. 2014; 28 (4): 323– 9. DOI: 10.1007/s10557–014–6536–7. PMID: 24984883.
7. Bhatt D. L., Grosser T., Dong J. F. et al. Enteric Coating and Aspi- rin Nonresponsiveness in Patients With Type 2 Diabetes Mel- litus. J Am Coll Cardiol. 2017; 69 (6): 603–12. DOI: 10.1016/j. jacc. 2016.11.050. PMID: 28089180.
8. Maree A. O., Curtin R. J., Dooley M. et al. Platelet response to low- dose enteric-coated aspirin in patients with stable cardiovascu- lar disease. J Am Col Cardiol. 2005; 46: 1258–63. DOI: 10.1016/j. jacc. 2005.06.058. PMID: 16198840.
9. Homoródi N., Kovács E. G., Leé S. et al. The lack of aspirin resis- tance in patients with coronary artery disease. J Transl Med. 2016; 14: 74. DOI: 10.1186/s12967–016–0827–7. PMID: 26980433.
10. Santilli F., Simeone P., Liani R., Davì G. Platelets and diabetes mel- litus. Prostaglandins Other Lipid Mediat. 2015; 120: 28–39. DOI: 10.101/j. prostaglandins.2015.05.002. PMID: 25986598.
11. Habizal N. H., Abdul Halim S., Bhaskar S. et al. Prevalence of aspi- rin resistance in diabetic patients and its associated factors. Malays J Med Sci. 2015; 22 (1): 50–7. PMID: 25892950.
12. Agarkova S. N., Filatova O. V., Kostyuchenko G. I. Aggregative activity of platelets in blood of women with diabetes mellitus type 2 under taking acetylsalicylic acid. [Agregeatsionnaya aktivnost’ trombotsitov u zhenshchin s sakharnym diabetom 2 tipa pri pri- yome ASK]. Izvestiya AltGU. 2014; 2 (3): 15–9 (in Russ.).
13. Kaplon-Cieslicka A., Postula M., Rosiak M. et al. Younger age, high- er body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study. Cardiovasc Diabetol. 2014; 13: 112. DOI: 10.1186/s12933–014–0112–0. PMID: 25123549.
14. Kuliczkowski W., Gasior M., Pres D., Kaczmarski J. Aspirin ‘resis- tance’: impact on no-reflow, platelet and inflammatory biomark- ers in diabetics after ST-segment elevation myocardial infarc- tion. Cardiology. 2015; 131 (1): 41–50. DOI: 10.1159/000371793. PMID: 25832492.
15. Barkagan Z. S., Momot A. P. Diagnosis and controlled therapy of hemostasis disorders. [Diagnostika i kontroliruyemaya terapiya narusheniy gemostaza]. Moskva: N’yudiamed. 2008: 292 s (in Russ.).
16. Arslan Y., Yoldaş T. K., Zorlu Y. Interaction between vWF levels and aspirin resistance in ischemic stroke patients. Transl Stroke Res. 2013; 4 (5): 484–7. DOI: 10.1007/s12975–013–0259–0. PMID: 24323374.